Rezolute, Inc.
Business
Rezolute, Inc. is a late-stage rare disease pharmaceutical company developing ersodetug, a monoclonal antibody that modulates insulin receptor signaling to treat hypoglycemia caused by hyperinsulinism. The company is advancing ersodetug through Phase 3 clinical trials for congenital hyperinsulinism and tumor-induced hyperinsulinism, with topline results expected in late 2025 and mid-2026, respectively. Ersodetug has received Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation from the FDA, and PRIME and ILAP designations from European regulatory authorities. The company operates through a wholly-owned drug development program focused on addressing serious unmet medical needs in rare hyperinsulinism conditions.
Summary from 10-K filed 2025-09-17
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Research and development | 62 | 56 | 44 | 32 | 15 | |
| General and administrative | 18 | 15 | 12 | 9 | 8 | |
| Total operating expenses | 80 | 70 | 56 | 42 | 23 | |
| Operating loss | −80 | −70 | −56 | −42 | −23 | |
| Interest and other income, net | 5 | 5 | 4 | 80,000 | 63,000 | |
| Total non-operating income (expense), net | 5 | 2 | 4 | 783,000 | 2 | |
| Net loss | −74 | −68 | −52 | −41 | −21 | |
| Net unrealized gain on marketable debt securities | 72,000 | 272,000 | −351,000 | — | — | |
| Comprehensive loss | −74 | −68 | −52 | −41 | — | |
| Net loss per common share - basic (in dollars per share) | −0.98 | −1.33 | −1.01 | −2.26 | −2.72 | |
| Net loss per common share - diluted (in dollars per share) | −0.98 | −1.33 | −1.01 | −2.32 | −2.72 | |
| Weighted average number of common shares outstanding - basic (in shares) | 76 | 51 | 51 | 18 | 8 | |
| Weighted average number of common shares outstanding - diluted (in shares) | 76 | 51 | 51 | 19 | 8 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 94 | 70 | 16 | 150 | 41 | |
| Investments in marketable debt securities | 74 | 56 | 86 | — | — | |
| Prepaid expenses and other | 3 | 2 | 3 | 2 | 946,000 | |
| Total current assets | 171 | 129 | 105 | 152 | 42 | |
| Deposits and other | 3 | 2 | 148,000 | 148,000 | 191,000 | |
| Right-of-use assets | 1 | 2 | 2 | 152,000 | 396,000 | |
| Property and equipment, net | 72,000 | 103,000 | 139,000 | 16,000 | 29,000 | |
| Investments in marketable debt securities | — | 263,000 | 16 | — | — | |
| Total assets | 175 | 133 | 124 | 152 | 43 | |
| Accounts payable | 6 | 5 | 3 | 1 | 1 | |
| Accrued clinical and other | 3 | 2 | 507,000 | 1 | — | |
| Compensation and benefits | 2 | 2 | 883,000 | — | 77,000 | |
| Current portion of operating lease liabilities | 632,000 | 568,000 | 541,000 | 108,000 | 265,000 | |
| Total current liabilities | 12 | 10 | 5 | 2 | 2 | |
| Operating lease liabilities, net of current portion | 983,000 | 2 | 2 | 80,000 | 187,000 | |
| Embedded derivative liability | 468,000 | 468,000 | 412,000 | 407,000 | 387,000 | |
| Total liabilities | 13 | 12 | 8 | 3 | 17 | |
| Commitments and contingencies (Notes 5, 10 and 11) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 400,000 shares authorized; no shares issued | — | — | — | — | — | |
| Common stock, $0.001 par value; 165,000,000 and 100,000,000 shares authorized; issued and outstanding 86,995,985 and 53,245,824 shares as of June 30, 2025 and 2024, respectively | 87,000 | 53,000 | 37,000 | 34,000 | 8,000 | |
| Additional paid-in capital | 566 | 450 | 377 | 359 | 194 | |
| Accumulated other comprehensive loss | −7,000 | −79,000 | −351,000 | — | — | |
| Accumulated deficit | −404 | −329 | −261 | −209 | −168 | |
| Total shareholders' equity | 162 | 121 | 116 | 149 | 26 | |
| Total liabilities and shareholders' equity | 175 | 133 | 124 | 152 | 43 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Net loss | −74 | −68 | −52 | −41 | −21 | |
| Share-based compensation expense | 7 | 7 | 7 | 4 | 4 | |
| Non-cash lease expense | 532,000 | 526,000 | 352,000 | 243,000 | 290,000 | |
| Accretion of discounts and amortization of premiums on marketable debt securities, net | −2 | −3 | −1 | — | — | |
| Depreciation expense | 31,000 | 36,000 | 30,000 | 13,000 | 13,000 | |
| Increase in prepaid expenses, deposits, and other assets | −2 | −129,000 | −1 | −860,000 | −387,000 | |
| Increase in accounts payable | 1 | 1 | 2 | −11,000 | 142,000 | |
| Increase in accrued liabilities | 721,000 | 2 | 205,000 | 229,000 | — | |
| Net Cash Used in Operating Activities | −69 | −57 | −44 | −40 | −20 | |
| Purchase of marketable debt securities | −128 | −66 | −107 | — | — | |
| Proceeds from maturities of marketable debt securities | 114 | 115 | 6 | — | — | |
| Net Cash Provided by (Used in) Investing Activities | −15 | 49 | −101 | — | 0 | |
| Proceeds from exercise of stock options | 893,000 | 234,000 | — | — | — | |
| Net cash payment pursuant to Exchange Agreement | — | −3,000 | — | — | — | |
| Payment of offering costs | −1 | −315,000 | — | — | −4 | |
| Net Cash Provided by Financing Activities | 107 | 63 | 12 | 149 | 52 | |
| Net increase in cash and cash equivalents | 24 | 54 | −134 | 109 | 31 | |
| Cash paid for amounts included in the measurement of operating lease liabilities | 748,000 | 728,000 | 215,000 | 254,000 | 299,000 | |
| Operating lease liabilities incurred in exchange for right-of-use-assets | — | 352,000 | 2 | — | 302,000 | |
| Acquisition of treasury shares in exchange for issuing pre-funded warrant liability | — | 6 | — | — | — | |
| Receivable from exercise of stock options | 503,000 | 12,000 | — | — | — | |
| Payable for offering costs charged to additional paid-in capital | 35,000 | 548,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Rezolute, Inc.'s CIK number?
Rezolute, Inc.'s SEC CIK number is 0001509261 (1509261). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Rezolute, Inc.'s SEC filings?
All of Rezolute, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Rezolute, Inc. last report earnings?
Rezolute, Inc. (RZLT) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-059392). This is Rezolute, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Rezolute, Inc.'s most recent earnings 8-K?
Rezolute, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001104659-26-059392. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Rezolute, Inc.'s latest earnings 8-K →
Look up any company's CIK number →